Non-Small Cell Lung Cancer – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Non-Small Cell Lung Cancer – Pipeline Review, H2 2017’, provides an overview of the Non-Small Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer

The report reviews pipeline therapeutics for Non-Small Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Non-Small Cell Lung Cancer therapeutics and enlists all their major and minor projects

The report assesses Non-Small Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

3SBio Inc

4SC AG

AbbVie Inc

Ability Pharmaceuticals SL

ACEA Biosciences Inc

Adamed Sp z oo

Adaptimmune Therapeutics Plc

ADC Therapeutics Sarl

Aduro BioTech Inc

Advantagene Inc

Advaxis Inc

Advenchen Laboratories LLC

Agenus Inc

Allist Shanghai Pharmaceutical Technology Co Ltd

Altimmune Inc

Altor BioScience Corp

Amgen Inc

Andarix Pharmaceuticals Inc

AndroScience Corp

Apexigen Inc

Aptose Biosciences Inc

Argos Therapeutics Inc

Ariad Pharmaceuticals Inc

ARMO Biosciences Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Ascentage Pharma Group Corp Ltd

Astellas Pharma Inc

Asterias Biotherapeutics Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atreca Inc

Aurigene Discovery Technologies Ltd

Aurobindo Pharma Ltd

AVEO Pharmaceuticals Inc

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Hanmi Pharmaceutical Co Ltd

BerGenBio ASA

Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

BeyondSpring Pharmaceuticals Inc

Bicycle Therapeutics Ltd

Bio-Cancer Treatment International Ltd

Biocad

BioCancell Ltd

Biocon Ltd

Biohaven Pharmaceutical Holding Company Ltd

BioLineRx Ltd

Bionovis SA

Biothera Pharmaceutical Inc

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Boston Biomedical Inc

BrightPath Biotherapeutics Co Ltd

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Calithera Biosciences Inc

CanBas Co Ltd

Cantargia AB

Cascadian Therapeutics Inc

CASI Pharmaceuticals Inc

CBT Pharmaceuticals Inc

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Cellmid Ltd

Cellular Biomedicine Group Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

Cielo Therapeutics Inc

Cleave Biosciences Inc

Cleveland BioLabs Inc

Coherus BioSciences Inc

Corcept Therapeutics Inc

Cortice Biosciences Inc

Corvus Pharmaceuticals Inc

Critical Outcome Technologies Inc

CSPC Pharmaceutical Group Limited

CytomX Therapeutics Inc

Cytori Therapeutics Inc

DAE HWA Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

DanDrit Biotech A/S

Debiopharm International SA

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Denovo Biopharma LLC

Domainex Ltd

Double Bond Pharmaceutical International AB

Dr. Reddy's Laboratories Ltd

Dynavax Technologies Corp

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Eli Lilly and Co

EnGeneIC Ltd

EntreChem SL

Enumeral Biomedical Holdings Inc

Enzene Biosciences Ltd

EpiThany Inc

Epizyme Inc

Eudendron Srl

Evotec AG

Exelixis Inc

F-star Biotechnology Ltd

F. Hoffmann-La Roche Ltd

FibroStatin SL

Five Prime Therapeutics Inc

Formosa Laboratories Inc

Fountain Biopharma Inc

Fujifilm Holdings Corporation

G&E Herbal Biotechnology Co Ltd

G1 Therapeutics Inc

Galectin Therapeutics Inc

Gene Techno Science Co Ltd

Genelux Corp

Genentech Inc

Genmab A/S

Genocea Biosciences Inc

Genor BioPharma Co Ltd

Genosco Inc

Genzyme Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

GlycaNova Norway AS

Glycotope GmbH

Golden Biotechnology Corp

Gradalis Inc

Grunenthal GmbH

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

Heat Biologics Inc

Helix BioPharma Corp

Hemispherx Biopharma Inc

Heptares Therapeutics Ltd

HitGen LTD

Horizon Pharma Plc

Hutchison MediPharma Ltd

iCeutica Inc

Ideaya Biosciences Inc

Ignyta Inc

Immatics Biotechnologies GmbH

Immune Design Corp

Immune Pharmaceuticals Inc

ImmunGene Inc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Imugene Ltd

Incyte Corp

Infinity Pharmaceuticals Inc

Inflection Biosciences Ltd

Innovation Pharmaceuticals Inc

Innovent Biologics Inc

Inovio Pharmaceuticals Inc

Invectys SA

Inventiva

IO Biotech ApS

Io Therapeutics Inc

Iovance Biotherapeutics Inc

JHL Biotech Inc

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Jounce Therapeutics Inc

Juno Therapeutics Inc

Kadmon Corp LLC

Karyopharm Therapeutics Inc

Kite Pharma Inc

Kura Oncology Inc

Kyowa Hakko Kirin Co Ltd

Laboratoires Pierre Fabre SA

LATITUDE Pharmaceuticals Inc

Leap Therapeutics Inc

Les Laboratoires Servier SAS

Lidds AB

Loxo Oncology Inc

Luye Pharma Group Ltd

Lycera Corp

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

MallInckrodt Plc

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

Microlin Bio Inc

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Molecular Partners AG

MolMed SpA

Morphotek Inc

Multimmune GmbH

Mundipharma International Ltd

Mycenax Biotech Inc

NanoCarrier Co Ltd

NantKwest Inc

Natco Pharma Ltd

Nektar Therapeutics

Neumedicines Inc

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

Oncobiologics Inc

Oncolys BioPharma Inc

Oncolytics Biotech Inc

Ono Pharmaceutical Co Ltd

Onxeo SA

Optimum Therapeutics LLC

OSE Immunotherapeutics

Paranta Biosciences Ltd

Peptomyc SL

Peregrine Pharmaceuticals Inc

Pfizer Inc

Pharma Mar SA

Philogen SpA

Phosplatin Therapeutics LLC

Pique Therapeutics

Plexxikon Inc

Polaris Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

PsiOxus Therapeutics Ltd

Puma Biotechnology Inc

Purdue Pharma LP

Qilu Pharmaceutical Co Ltd

Qu Biologics Inc

Qurient Co Ltd

Rafael Pharmaceuticals Inc

RaQualia Pharma Inc

Reata Pharmaceuticals Inc

Recombio SL

Regeneron Pharmaceuticals Inc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

RS Research

Samyang Holdings Corp

Sanofi

Scancell Holdings Plc

SciClone Pharmaceuticals Inc

ScinoPharm Taiwan Ltd

Seattle Genetics Inc

Selvita SA

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Shanghai Pharmaceutical Co Ltd

Shionogi & Co Ltd

Sierra Oncology Inc

Sigma-Tau SpA

SignPath Pharma Inc

Simcere Pharmaceutical Group

Sino Biopharmaceutical Ltd

Sotio AS

Spotlight Innovation Inc

Starpharma Holdings Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

SuviCa Inc

Symphogen A/S

Synactix Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Synermore Biologics Co Ltd

Systimmune Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 13

Non-Small Cell Lung Cancer - Overview 14

Non-Small Cell Lung Cancer - Therapeutics Development 15

Non-Small Cell Lung Cancer - Therapeutics Assessment 88

Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 123

Non-Small Cell Lung Cancer - Drug Profiles 266

Non-Small Cell Lung Cancer - Dormant Projects 2564

Non-Small Cell Lung Cancer - Discontinued Products 2586

Non-Small Cell Lung Cancer - Product Development Milestones 2595

Appendix 2606

List of Tables

List of Tables

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2017 86

Number of Products under Development by Companies, H2 2017 88

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 89

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 90

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 91

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 92

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 93

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 94

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 95

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 96

Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 97

Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 98

Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017 99

Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017 100

Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017 101

Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017 102

Number of Products under Development by Companies, H2 2017 (Contd..15), H2 2017 103

Number of Products under Development by Companies, H2 2017 (Contd..16), H2 2017 104

Number of Products under Development by Companies, H2 2017 (Contd..17), H2 2017 105

Number of Products under Development by Companies, H2 2017 (Contd..18), H2 2017 106

Number of Products under Development by Companies, H2 2017 (Contd..19), H2 2017 107

Number of Products under Development by Companies, H2 2017 (Contd..20), H2 2017 108

Number of Products under Development by Companies, H2 2017 (Contd..21), H2 2017 109

Number of Products under Development by Universities/Institutes, H2 2017 110

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 112

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 113

Products under Development by Companies, H2 2017 114

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 115

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 116

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 117

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 118

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 119

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 120

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 121

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 122

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 123

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 124

Products under Development by Companies, H2 2017 (Contd..11), H2 2017 125

Products under Development by Companies, H2 2017 (Contd..12), H2 2017 126

Products under Development by Companies, H2 2017 (Contd..13), H2 2017 127

Products under Development by Companies, H2 2017 (Contd..14), H2 2017 128

Products under Development by Companies, H2 2017 (Contd..15), H2 2017 129

Products under Development by Companies, H2 2017 (Contd..16), H2 2017 130

Products under Development by Companies, H2 2017 (Contd..17), H2 2017 131

Products under Development by Companies, H2 2017 (Contd..18), H2 2017 132

Products under Development by Companies, H2 2017 (Contd..19), H2 2017 133

Products under Development by Companies, H2 2017 (Contd..20), H2 2017 134

Products under Development by Companies, H2 2017 (Contd..21), H2 2017 135

Products under Development by Companies, H2 2017 (Contd..22), H2 2017 136

Products under Development by Companies, H2 2017 (Contd..23), H2 2017 137

Products under Development by Companies, H2 2017 (Contd..24), H2 2017 138

Products under Development by Companies, H2 2017 (Contd..25), H2 2017 139

Products under Development by Companies, H2 2017 (Contd..26), H2 2017 140

Products under Development by Companies, H2 2017 (Contd..27), H2 2017 141

Products under Development by Companies, H2 2017 (Contd..28), H2 2017 142

Products under Development by Companies, H2 2017 (Contd..29), H2 2017 143

Products under Development by Companies, H2 2017 (Contd..30), H2 2017 144

Products under Development by Companies, H2 2017 (Contd..31), H2 2017 145

Products under Development by Companies, H2 2017 (Contd..32), H2 2017 146

Products under Development by Companies, H2 2017 (Contd..33), H2 2017 147

Products under Development by Companies, H2 2017 (Contd..34), H2 2017 148

Products under Development by Companies, H2 2017 (Contd..35), H2 2017 149

Products under Development by Companies, H2 2017 (Contd..36), H2 2017 150

Products under Development by Companies, H2 2017 (Contd..37), H2 2017 151

Products under Development by Companies, H2 2017 (Contd..38), H2 2017 152

Products under Development by Companies, H2 2017 (Contd..39), H2 2017 153

Products under Development by Companies, H2 2017 (Contd..40), H2 2017 154

Products under Development by Universities/Institutes, H2 2017 155

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 156

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 157

Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 158

Number of Products by Stage and Target, H2 2017 160

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 161

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 162

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 163

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 164

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 165

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 166

Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 167

Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017 168

Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017 169

Number of Products by Stage and Target, H2 2017 (Contd..10), H2 2017 170

Number of Products by Stage and Target, H2 2017 (Contd..11), H2 2017 171

Number of Products by Stage and Target, H2 2017 (Contd..12), H2 2017 172

Number of Products by Stage and Target, H2 2017 (Contd..13), H2 2017 173

Number of Products by Stage and Target, H2 2017 (Contd..14), H2 2017 174

Number of Products by Stage and Mechanism of Action, H2 2017 176

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 177

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 178

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 179

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 180

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 181

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 182

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 183

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017 184

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017 185

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..10), H2 2017 186

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..11), H2 2017 187

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..12), H2 2017 188

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..13), H2 2017 189

Number of Products by Stage and Route of Administration, H2 2017 191

Number of Products by Stage and Molecule Type, H2 2017 193

Non-Small Cell Lung Cancer – Pipeline by 3-V Biosciences Inc, H2 2017 194

Non-Small Cell Lung Cancer – Pipeline by 3SBio Inc, H2 2017 194

Non-Small Cell Lung Cancer – Pipeline by 4SC AG, H2 2017 196

Non-Small Cell Lung Cancer – Pipeline by AbbVie Inc, H2 2017 196

Non-Small Cell Lung Cancer – Pipeline by Ability Pharmaceuticals SL, H2 2017 197

Non-Small Cell Lung Cancer – Pipeline by ACEA Biosciences Inc, H2 2017 197

Non-Small Cell Lung Cancer – Pipeline by Adamed Sp z oo, H2 2017 198

Non-Small Cell Lung Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2017 198

Non-Small Cell Lung Cancer – Pipeline by ADC Therapeutics Sarl, H2 2017 198

Non-Small Cell Lung Cancer – Pipeline by Aduro BioTech Inc, H2 2017 199

Non-Small Cell Lung Cancer – Pipeline by Advantagene Inc, H2 2017 199

Non-Small Cell Lung Cancer – Pipeline by Advaxis Inc, H2 2017 200

Non-Small Cell Lung Cancer – Pipeline by Advenchen Laboratories LLC, H2 2017 200

Non-Small Cell Lung Cancer – Pipeline by Agenus Inc, H2 2017 201

Non-Small Cell Lung Cancer – Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017 201

Non-Small Cell Lung Cancer – Pipeline by Altimmune Inc, H2 2017 201

Non-Small Cell Lung Cancer – Pipeline by Altor BioScience Corp, H2 2017 202

Non-Small Cell Lung Cancer – Pipeline by Amgen Inc, H2 2017 203

Non-Small Cell Lung Cancer – Pipeline by Andarix Pharmaceuticals Inc, H2 2017 203

Non-Small Cell Lung Cancer – Pipeline by AndroScience Corp, H2 2017 203

Non-Small Cell Lung Cancer – Pipeline by Apexigen Inc, H2 2017 204

Non-Small Cell Lung Cancer – Pipeline by Aptose Biosciences Inc, H2 2017 204

Non-Small Cell Lung Cancer – Pipeline by Argos Therapeutics Inc, H2 2017 205

Non-Small Cell Lung Cancer – Pipeline by Ariad Pharmaceuticals Inc, H2 2017 205

Non-Small Cell Lung Cancer – Pipeline by ARMO Biosciences Inc, H2 2017 206

Non-Small Cell Lung Cancer – Pipeline by ArQule Inc, H2 2017 206

Non-Small Cell Lung Cancer – Pipeline by Array BioPharma Inc, H2 2017 207

Non-Small Cell Lung Cancer – Pipeline by Asana BioSciences LLC, H2 2017 207

Non-Small Cell Lung Cancer – Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017 207

Non-Small Cell Lung Cancer – Pipeline by Astellas Pharma Inc, H2 2017 208

Non-Small Cell Lung Cancer – Pipeline by Asterias Biotherapeutics Inc, H2 2017 208

Non-Small Cell Lung Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2017 209

Non-Small Cell Lung Cancer – Pipeline by AstraZeneca Plc, H2 2017 210

Non-Small Cell Lung Cancer – Pipeline by Atreca Inc, H2 2017 210

Non-Small Cell Lung Cancer – Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 211

Non-Small Cell Lung Cancer – Pipeline by Aurobindo Pharma Ltd, H2 2017 211

Non-Small Cell Lung Cancer – Pipeline by AVEO Pharmaceuticals Inc, H2 2017 212

Non-Small Cell Lung Cancer – Pipeline by Basilea Pharmaceutica Ltd, H2 2017 212

Non-Small Cell Lung Cancer – Pipeline by Batu Biologics Inc, H2 2017 213

Non-Small Cell Lung Cancer – Pipeline by Bavarian Nordic A/S, H2 2017 213

Non-Small Cell Lung Cancer – Pipeline by Bayer AG, H2 2017 214

Non-Small Cell Lung Cancer – Pipeline by BeiGene Ltd, H2 2017 215

Non-Small Cell Lung Cancer – Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017 215

Non-Small Cell Lung Cancer – Pipeline by BerGenBio ASA, H2 2017 215

Non-Small Cell Lung Cancer – Pipeline by Beta Pharma Inc, H2 2017 216

Non-Small Cell Lung Cancer – Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017 216

Non-Small Cell Lung Cancer – Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017 217

Non-Small Cell Lung Cancer – Pipeline by Bicycle Therapeutics Ltd, H2 2017 217

Non-Small Cell Lung Cancer – Pipeline by Bio-Cancer Treatment International Ltd, H2 2017 217

Non-Small Cell Lung Cancer – Pipeline by Biocad, H2 2017 218

Non-Small Cell Lung Cancer – Pipeline by BioCancell Ltd, H2 2017 218

Non-Small Cell Lung Cancer – Pipeline by Biocon Ltd, H2 2017 219

Non-Small Cell Lung Cancer – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017 219

Non-Small Cell Lung Cancer – Pipeline by BioLineRx Ltd, H2 2017 220

Non-Small Cell Lung Cancer – Pipeline by Bionovis SA, H2 2017 220

Non-Small Cell Lung Cancer – Pipeline by Biothera Pharmaceutical Inc, H2 2017 220

Non-Small Cell Lung Cancer – Pipeline by Blueprint Medicines Corp, H2 2017 221

Non-Small Cell Lung Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2017 221

Non-Small Cell Lung Cancer – Pipeline by Boston Biomedical Inc, H2 2017 222

Non-Small Cell Lung Cancer – Pipeline by BrightPath Biotherapeutics Co Ltd, H2 2017 222

Non-Small Cell Lung Cancer – Pipeline by Bristol-Myers Squibb Co, H2 2017 223

Non-Small Cell Lung Cancer – Pipeline by Cadila Healthcare Ltd, H2 2017 224

Non-Small Cell Lung Cancer – Pipeline by Calithera Biosciences Inc, H2 2017 224

Non-Small Cell Lung Cancer – Pipeline by CanBas Co Ltd, H2 2017 225

Non-Small Cell Lung Cancer – Pipeline by Cantargia AB, H2 2017 225

Non-Small Cell Lung Cancer – Pipeline by Cascadian Therapeutics Inc, H2 2017 226

Non-Small Cell Lung Cancer – Pipeline by CASI Pharmaceuticals Inc, H2 2017 226

Non-Small Cell Lung Cancer – Pipeline by CBT Pharmaceuticals Inc, H2 2017 226

Non-Small Cell Lung Cancer – Pipeline by Celgene Corp, H2 2017 227

Non-Small Cell Lung Cancer – Pipeline by Cell Medica Ltd, H2 2017 228

Non-Small Cell Lung Cancer – Pipeline by Celldex Therapeutics Inc, H2 2017 228

Non-Small Cell Lung Cancer – Pipeline by Cellmid Ltd, H2 2017 229

Non-Small Cell Lung Cancer – Pipeline by Cellular Biomedicine Group Inc, H2 2017 229

Non-Small Cell Lung Cancer – Pipeline by Checkpoint Therapeutics Inc, H2 2017 230

Non-Small Cell Lung Cancer – Pipeline by Chipscreen Biosciences Ltd, H2 2017 230

Non-Small Cell Lung Cancer – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 231

Non-Small Cell Lung Cancer – Pipeline by Cielo Therapeutics Inc, H2 2017 231

Non-Small Cell Lung Cancer – Pipeline by Cleave Biosciences Inc, H2 2017 231

Non-Small Cell Lung Cancer – Pipeline by Cleveland BioLabs Inc, H2 2017 232

Non-Small Cell Lung Cancer – Pipeline by Coherus BioSciences Inc, H2 2017 232

Non-Small Cell Lung Cancer – Pipeline by Corcept Therapeutics Inc, H2 2017 233

Non-Small Cell Lung Cancer – Pipeline by Cortice Biosciences Inc, H2 2017 233

Non-Small Cell Lung Cancer – Pipeline by Corvus Pharmaceuticals Inc, H2 2017 234

Non-Small Cell Lung Cancer – Pipeline by Critical Outcome Technologies Inc, H2 2017 234

Non-Small Cell Lung Cancer – Pipeline by CSPC Pharmaceutical Group Limited, H2 2017 235

Non-Small Cell Lung Cancer – Pipeline by CytomX Therapeutics Inc, H2 2017 235

Non-Small Cell Lung Cancer – Pipeline by Cytori Therapeutics Inc, H2 2017 236

Non-Small Cell Lung Cancer – Pipeline by DAE HWA Pharmaceutical Co Ltd, H2 2017 236

Non-Small Cell Lung Cancer – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 237

Non-Small Cell Lung Cancer – Pipeline by DanDrit Biotech A/S, H2 2017 237

Non-Small Cell Lung Cancer – Pipeline by Debiopharm International SA, H2 2017 238

Non-Small Cell Lung Cancer – Pipeline by DEKK-TEC Inc, H2 2017 238

Non-Small Cell Lung Cancer – Pipeline by DelMar Pharmaceuticals Inc, H2 2017 238

Non-Small Cell Lung Cancer – Pipeline by Denovo Biopharma LLC, H2 2017 239

Non-Small Cell Lung Cancer – Pipeline by Domainex Ltd, H2 2017 239

Non-Small Cell Lung Cancer – Pipeline by Double Bond Pharmaceutical International AB, H2 2017 240

Non-Small Cell Lung Cancer – Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017 240

Non-Small Cell Lung Cancer – Pipeline by Dynavax Technologies Corp, H2 2017 241

Non-Small Cell Lung Cancer – Pipeline by eFFECTOR Therapeutics Inc, H2 2017 241

Non-Small Cell Lung Cancer – Pipeline by Eisai Co Ltd, H2 2017 242

Non-Small Cell Lung Cancer – Pipeline by Eleison Pharmaceuticals LLC, H2 2017 242

Non-Small Cell Lung Cancer – Pipeline by Eli Lilly and Co, H2 2017 243

Non-Small Cell Lung Cancer – Pipeline by EnGeneIC Ltd, H2 2017 244

Non-Small Cell Lung Cancer – Pipeline by EntreChem SL, H2 2017 244

Non-Small Cell Lung Cancer – Pipeline by Enumeral Biomedical Holdings Inc, H2 2017 244

Non-Small Cell Lung Cancer – Pipeline by Enzene Biosciences Ltd, H2 2017 245

Non-Small Cell Lung Cancer – Pipeline by EpiThany Inc, H2 2017 245

Non-Small Cell Lung Cancer – Pipeline by Epizyme Inc, H2 2017 246

Non-Small Cell Lung Cancer – Pipeline by Eudendron Srl, H2 2017 246

Non-Small Cell Lung Cancer – Pipeline by Evotec AG, H2 2017 247

Non-Small Cell Lung Cancer – Pipeline by Exelixis Inc, H2 2017 247

Non-Small Cell Lung Cancer – Pipeline by F-star Biotechnology Ltd, H2 2017 247

Non-Small Cell Lung Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 248

Non-Small Cell Lung Cancer – Pipeline by FibroStatin SL, H2 2017 248

Non-Small Cell Lung Cancer – Pipeline by Five Prime Therapeutics Inc, H2 2017 249

Non-Small Cell Lung Cancer – Pipeline by Formosa Laboratories Inc, H2 2017 249

Non-Small Cell Lung Cancer – Pipeline by Fountain Biopharma Inc, H2 2017 250

Non-Small Cell Lung Cancer – Pipeline by Fujifilm Holdings Corporation, H2 2017 250

Non-Small Cell Lung Cancer – Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017 251

Non-Small Cell Lung Cancer – Pipeline by G1 Therapeutics Inc, H2 2017 251

Non-Small Cell Lung Cancer – Pipeline by Galectin Therapeutics Inc, H2 2017 252

Non-Small Cell Lung Cancer – Pipeline by Gene Techno Science Co Ltd, H2 2017 252

Non-Small Cell Lung Cancer – Pipeline by Genelux Corp, H2 2017 252

Non-Small Cell Lung Cancer – Pipeline by Genentech Inc, H2 2017 253

Non-Small Cell Lung Cancer – Pipeline by Genmab A/S, H2 2017 253

Non-Small Cell Lung Cancer – Pipeline by Genocea Biosciences Inc, H2 2017 254

Non-Small Cell Lung Cancer – Pipeline by Genor BioPharma Co Ltd, H2 2017 254

Non-Small Cell Lung Cancer – Pipeline by Genosco Inc, H2 2017 255

Non-Small Cell Lung Cancer – Pipeline by Genzyme Corp, H2 2017 255

Non-Small Cell Lung Cancer – Pipeline by Gilead Sciences Inc, H2 2017 256

Non-Small Cell Lung Cancer – Pipeline by GlaxoSmithKline Plc, H2 2017 256

Non-Small Cell Lung Cancer – Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 257

Non-Small Cell Lung Cancer – Pipeline by GlycaNova Norway AS, H2 2017 257

Non-Small Cell Lung Cancer – Pipeline by Glycotope GmbH, H2 2017 258

Non-Small Cell Lung Cancer – Pipeline by Golden Biotechnology Corp, H2 2017 258

Non-Small Cell Lung Cancer – Pipeline by Gradalis Inc, H2 2017 258

Non-Small Cell Lung Cancer – Pipeline by Grunenthal GmbH, H2 2017 259

Non-Small Cell Lung Cancer – Pipeline by Halozyme Therapeutics Inc, H2 2017 259

Non-Small Cell Lung Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 260

Non-Small Cell Lung Cancer – Pipeline by Heat Biologics Inc, H2 2017 260

Non-Small Cell Lung Cancer – Pipeline by Helix BioPharma Corp, H2 2017 261

Non-Small Cell Lung Cancer – Pipeline by Hemispherx Biopharma Inc, H2 2017 261

Non-Small Cell Lung Cancer – Pipeline by Heptares Therapeutics Ltd, H2 2017 262

Non-Small Cell Lung Cancer – Pipeline by HitGen LTD, H2 2017 262

Non-Small Cell Lung Cancer – Pipeline by Horizon Pharma Plc, H2 2017 262

Non-Small Cell Lung Cancer – Pipeline by Hutchison MediPharma Ltd, H2 2017 263

Non-Small Cell Lung Cancer – Pipeline by iCeutica Inc, H2 2017 263

Non-Small Cell Lung Cancer – Pipeline by Ideaya Biosciences Inc, H2 2017 264

Non-Small Cell Lung Cancer – Pipeline by Ignyta Inc, H2 2017 264

Non-Small Cell Lung Cancer – Pipeline by Immatics Biotechnologies GmbH, H2 2017 264

Non-Small Cell Lung Cancer – Pipeline by Immune Design Corp, H2 2017 265

Non-Small Cell Lung Cancer – Pipeline by Immune Pharmaceuticals Inc, H2 2017 265

Non-Small Cell Lung Cancer – Pipeline by ImmunGene Inc, H2 2017 266

Non-Small Cell Lung Cancer – Pipeline by Immunocore Ltd, H2 2017 266

Non-Small Cell Lung Cancer – Pipeline by ImmunoGen Inc, H2 2017 267

Non-Small Cell Lung Cancer – Pipeline by Immunomedics Inc, H2 2017 267

Non-Small Cell Lung Cancer – Pipeline by Imugene Ltd, H2 2017 268

Non-Small Cell Lung Cancer – Pipeline by Incyte Corp, H2 2017 268

Non-Small Cell Lung Cancer – Pipeline by Infinity Pharmaceuticals Inc, H2 2017 269

Non-Small Cell Lung Cancer – Pipeline by Inflection Biosciences Ltd, H2 2017 269

Non-Small Cell Lung Cancer – Pipeline by Innovation Pharmaceuticals Inc, H2 2017 270

Non-Small Cell Lung Cancer – Pipeline by Innovent Biologics Inc, H2 2017 270

Non-Small Cell Lung Cancer – Pipeline by Inovio Pharmaceuticals Inc, H2 2017 270

Non-Small Cell Lung Cancer – Pipeline by Invectys SA, H2 2017 271

Non-Small Cell Lung Cancer – Pipeline by Inventiva, H2 2017 271

Non-Small Cell Lung Cancer – Pipeline by IO Biotech ApS, H2 2017 272

Non-Small Cell Lung Cancer – Pipeline by Io Therapeutics Inc, H2 2017 272

Non-Small Cell Lung Cancer – Pipeline by Iovance Biotherapeutics Inc, H2 2017 272

Non-Small Cell Lung Cancer – Pipeline by JHL Biotech Inc, H2 2017 273

Non-Small Cell Lung Cancer – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017 273

Non-Small Cell Lung Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 274

Non-Small Cell Lung Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017 274

Non-Small Cell Lung Cancer – Pipeline by Johnson & Johnson, H2 2017 275

Non-Small Cell Lung Cancer – Pipeline by Jounce Therapeutics Inc, H2 2017 276

Non-Small Cell Lung Cancer – Pipeline by Juno Therapeutics Inc, H2 2017 276

Non-Small Cell Lung Cancer – Pipeline by Kadmon Corp LLC, H2 2017 276

Non-Small Cell Lung Cancer – Pipeline by Karyopharm Therapeutics Inc, H2 2017 277

Non-Small Cell Lung Cancer – Pipeline by Kite Pharma Inc, H2 2017 277

Non-Small Cell Lung Cancer – Pipeline by Kura Oncology Inc, H2 2017 278

Non-Small Cell Lung Cancer – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 278

Non-Small Cell Lung Cancer – Pipeline by Laboratoires Pierre Fabre SA, H2 2017 279

Non-Small Cell Lung Cancer – Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017 279

Non-Small Cell Lung Cancer – Pipeline by Leap Therapeutics Inc, H2 2017 280

Non-Small Cell Lung Cancer – Pipeline by Les Laboratoires Servier SAS, H2 2017 280

Non-Small Cell Lung Cancer – Pipeline by Lidds AB, H2 2017 280

Non-Small Cell Lung Cancer – Pipeline by Loxo Oncology Inc, H2 2017 281

Non-Small Cell Lung Cancer – Pipeline by Luye Pharma Group Ltd, H2 2017 281

Non-Small Cell Lung Cancer – Pipeline by Lycera Corp, H2 2017 282

Non-Small Cell Lung Cancer – Pipeline by MabVax Therapeutics Holdings Inc, H2 2017 282

Non-Small Cell Lung Cancer – Pipeline by MacroGenics Inc, H2 2017 283

Non-Small Cell Lung Cancer – Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 283

Non-Small Cell Lung Cancer – Pipeline by MallInckrodt Plc, H2 2017 284

Non-Small Cell Lung Cancer – Pipeline by Mebiopharm Co Ltd, H2 2017 284

Non-Small Cell Lung Cancer – Pipeline by MedImmune LLC, H2 2017 285

Non-Small Cell Lung Cancer – Pipeline by Merck & Co Inc, H2 2017 285

Non-Small Cell Lung Cancer – Pipeline by Merck KGaA, H2 2017 286

Non-Small Cell Lung Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 287

Non-Small Cell Lung Cancer – Pipeline by Mersana Therapeutics Inc, H2 2017 287

Non-Small Cell Lung Cancer – Pipeline by Merus NV, H2 2017 288

Non-Small Cell Lung Cancer – Pipeline by Microlin Bio Inc, H2 2017 288

Non-Small Cell Lung Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 288

Non-Small Cell Lung Cancer – Pipeline by Mirati Therapeutics Inc, H2 2017 289

Non-Small Cell Lung Cancer – Pipeline by Moderna Therapeutics Inc, H2 2017 289

Non-Small Cell Lung Cancer – Pipeline by Molecular Partners AG, H2 2017 290

Non-Small Cell Lung Cancer – Pipeline by MolMed SpA, H2 2017 290

Non-Small Cell Lung Cancer – Pipeline by Morphotek Inc, H2 2017 291

Non-Small Cell Lung Cancer – Pipeline by Multimmune GmbH, H2 2017 291

Non-Small Cell Lung Cancer – Pipeline by Mundipharma International Ltd, H2 2017 291

Non-Small Cell Lung Cancer – Pipeline by Mycenax Biotech Inc, H2 2017 292

Non-Small Cell Lung Cancer – Pipeline by NanoCarrier Co Ltd, H2 2017 292

Non-Small Cell Lung Cancer – Pipeline by NantKwest Inc, H2 2017 293

Non-Small Cell Lung Cancer – Pipeline by Natco Pharma Ltd, H2 2017 293

Non-Small Cell Lung Cancer – Pipeline by Nektar Therapeutics, H2 2017 294

Non-Small Cell Lung Cancer – Pipeline by Neumedicines Inc, H2 2017 294

Non-Small Cell Lung Cancer – Pipeline by NewLink Genetics Corp, H2 2017 295

Non-Small Cell Lung Cancer – Pipeline by Northwest Biotherapeutics Inc, H2 2017 295

Non-Small Cell Lung Cancer – Pipeline by Novartis AG, H2 2017 297

Non-Small Cell Lung Cancer – Pipeline by Oncobiologics Inc, H2 2017 298

Non-Small Cell Lung Cancer – Pipeline by Oncolys BioPharma Inc, H2 2017 298

Non-Small Cell Lung Cancer – Pipeline by Oncolytics Biotech Inc, H2 2017 299

Non-Small Cell Lung Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 299

Non-Small Cell Lung Cancer – Pipeline by Onxeo SA, H2 2017 300

Non-Small Cell Lung Cancer – Pipeline by Optimum Therapeutics LLC, H2 2017 300

List of Figures

List of Figures

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2017 86

Number of Products under Development by Companies, H2 2017 87

Number of Products under Development by Universities/Institutes, H2 2017 110

Number of Products by Top 10 Targets, H2 2017 159

Number of Products by Stage and Top 10 Targets, H2 2017 159

Number of Products by Top 10 Mechanism of Actions, H2 2017 175

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 175

Number of Products by Top 10 Routes of Administration, H2 2017 190

Number of Products by Stage and Top 10 Routes of Administration, H2 2017 190

Number of Products by Top 10 Molecule Types, H2 2017 192

Number of Products by Stage and Top 10 Molecule Types, H2 2017 192

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports